Arcus Biosciences, Inc. (RCUS) Stock

NYSE: RCUSClinical-stage biopharmaceutical company developing immuno-oncology therapies.

Arcus Biosciences stock price chart

RCUS interactive chart →

RCUS stock quote & key statistics

Arcus Biosciences earnings per share

Income →
Earnings per share

Arcus Biosciences revenue & net income

Income →
RevenueNet income

Arcus Biosciences annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$247.0M-$353.0M-$3.30
FY2024$258.0M-$283.0M-$2.86
FY2023$117.0M-$307.0M-$4.15
FY2022$112.0M-$267.0M-$3.72
FY2021$383.0M$53.0M$0.43

Fiscal year ending December 31. Source: company filings via EODHD.

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. is a prominent clinical-stage biopharmaceutical firm focused on pioneering cancer therapies within the United States. Established in 2015, Arcus Biosciences develops and commercializes a diverse pipeline of innovative treatments aimed at addressing critical unmet needs in oncology. Central to its portfolio are several promising candidates currently advancing through clinical trials.

Among its leading investigational therapies is Etrumadenant, a Phase 1b/2 dual A2a/A2b adenosine receptor antagonist designed to modulate the tumor microenvironment. Additionally, Zimberelimab, an anti-PD-1 antibody, is progressing through a Phase 1b trial as a monotherapy, showcasing potential in immune checkpoint inhibition strategies.

Arcus Biosciences is also actively developing Domvanalimab, an anti-TIGIT monoclonal antibody in Phase 2 development. This therapy is being studied in combination with Zimberelimab for first-line treatment of metastatic non-small cell lung cancer, highlighting the company's commitment to innovative combination therapies. Moreover, Quemliclustat, a Phase 1/1b small-molecule CD73 inhibitor, and AB521, an oral HIF-2a inhibitor in Phase 1, further underscore Arcus Biosciences' dedication to advancing novel approaches against challenging cancers such as metastatic pancreatic cancer and von Hippel-Lindau disease.

Strategic collaborations bolster Arcus Biosciences robust research and development efforts. These include partnerships with AstraZeneca and BVF Partners L.P., aiming to evaluate Domvanalimab in combination with Imfinzi in Phase 3 trials. Additionally, the company has formed key alliances with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to advance innovative treatments like anti-CD39 antibodies, illustrating its collaborative approach to expanding therapeutic options for cancer patients worldwide. Headquartered in Hayward, California, Arcus Biosciences, Inc. remains at the forefront of advancing transformative oncology treatments through rigorous scientific innovation and strategic partnerships.

Arcus Biosciences stock FAQ

What is the Arcus Biosciences stock ticker symbol?

Arcus Biosciences, Inc. trades on the NYSE under the ticker symbol RCUS.

What sector and industry is Arcus Biosciences in?

Arcus Biosciences, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Arcus Biosciences have?

Arcus Biosciences, Inc. has about 601 full-time employees.

What were Arcus Biosciences's revenue and earnings last fiscal year?

Arcus Biosciences reported revenue of $247.0M and net income of -$353.0M in fiscal 2025, with earnings per share of -$3.30. Revenue declined 4.3% from the prior year.

Is Arcus Biosciences in the S&P SmallCap 600?

Yes. Arcus Biosciences, Inc. (RCUS) is a component of the S&P SmallCap 600, the benchmark index of profitable U.S. small-cap stocks.

Is Arcus Biosciences in the Russell 2000?

Yes. Arcus Biosciences, Inc. (RCUS) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Arcus Biosciences go public?

Arcus Biosciences stock began trading on March 15, 2018.

S&P SmallCap 600 Biotechnology stocks

All S&P SmallCap 600 →